Stock ENTX ENTERA BIO LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Entera Bio Ltd. Share Price

Equities

ENTX

IL0011429839

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
1.98 USD -1.00% Intraday chart for Entera Bio Ltd. -0.50% +230.00%
04-08 Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research CI
03-26 Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 70.25M 5.62B
Net income 2024 * -9M -720M Net income 2025 * -28M -2.24B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-7.92 x
P/E ratio 2025 *
-3.67 x
Employees 18
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.93%
More Fundamentals * Assessed data

Chart Entera Bio Ltd.

Dynamic Chart

Latest news about Entera Bio Ltd.

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research CI
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months CI
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Premarket Gainers MT
Top Premarket Gainers MT
Entera Bio Ltd. announced that it has received $6.610594 million in funding CI
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding CI
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform CI
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide Phase 3 Program CI
Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting CI
Entera Bio Ltd. Announces Collaboration with OPKO Biologics, Inc. to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes CI
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research Annual Meeting CI
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Analyst Recommendations on Entera Bio Ltd.

HC Wainwright Initiates Entera Bio at Buy With $10 Price Target MT
B. Riley Securities Trims Entera Bio's Price Target to $5 from $6 to Reflect Delayed Clinical/Regulatory Path, Keeps Buy Rating MT
Maxim Group Adjusts Entera Bio Price Target to $6 From $10, Maintains Buy Rating MT
B. Riley Lowers Entera Bio's Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
ENTERA BIO : B. Riley Lowers Entera Bio's PT to $11 from $14 Following Results from Phase II Study of EB613 Osteoporosis Treatment, Keeps Buy Rating MT
More recommendations

Press releases Entera Bio Ltd.

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research AQ
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months AQ
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome AQ
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates AQ
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement AQ
More press releases

Quotes and Performance

1 day-1.00%
1 week-0.50%
Current month+18.56%
1 month+27.74%
3 months+127.43%
6 months+192.04%
Current year+230.00%
More quotes

Highs and lows

1 week
1.81
Extreme 1.8101
2.26
1 month
1.54
Extreme 1.54
3.35
Current year
0.58
Extreme 0.5826
3.35
1 year
0.52
Extreme 0.52
3.35
3 years
0.47
Extreme 0.4722
8.68
5 years
0.00
Extreme 0
10.16
10 years
0.00
Extreme 0
10.16
More quotes

Managers and Directors - Entera Bio Ltd.

Managers TitleAgeSince
Miranda Toledano CEO
 Chief Executive Officer 47 26/09/18
Dana Yaacov Garbeli DFI
 Director of Finance/CFO 40 31/05/19
Anke Hoppe CTO
 Chief Tech/Sci/R&D Officer - 31/12/17
Members of the board TitleAgeSince
Gerald Lieberman CHM
 Chairman 77 31/12/13
Roger Garceau BRD
 Director/Board Member 70 29/02/16
Gerald Ostrov BRD
 Director/Board Member 73 09/01/19
More insiders

Quotes

Date Price Change Volume
26/04/24 1.98 -1.00% 118,877
25/04/24 2 -3.38% 117,782
24/04/24 2.07 -6.76% 163,385
23/04/24 2.22 +8.29% 115,725
22/04/24 2.05 +3.02% 172,695

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes

Company Profile

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Sector
Biotechnology & Medical Research
Calendar
26/06/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.98 USD
Average target price
10 USD
Spread / Average Target
+405.05%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ENTERA BIO LTD. Stock Entera Bio Ltd.
+230.00% 70.25M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ENTX Stock